All In Biotech

NDA 202992 · Sanofi Aventis US

Aubagio

Teriflunomide · Oral · Pyrimidine Synthesis Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Sep 12, 2012

Approved uses

4

Original approval plus efficacy supplements

Registered trials

58

30 Phase 3, 3 recruiting

FAERS reports

45,107

19,624 serious, 729 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY and EMBRYOFETAL TOXICITY Hepatotoxicity Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with AUBAGIO in the postmarketing setting [see Warnings and Precautions (5.1) ] . Concomitant use of AUBAGIO with other hepatotoxic drugs may increase the risk of severe liver injury. Obtain transaminase and bilirubin levels within 6 months before initiation of AUBAGIO therapy. Monitor ALT levels at least monthly for six months after starting AUBAGIO [see Warnings and Precautions (5.1) ]. If drug induced liver injury is suspected, discontinue AUBAGIO and start an accelerated elimination procedure with cholestyramine or charcoal [see Warnings and Precautions (5.3) ] . AUBAGIO is contraindicated in patients with severe hepatic impairment [see Contraindications (4) ] ....

What it is approved for

From the label in effect Feb 20, 2026.

AUBAGIO ® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AUBAGIO is a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Mechanism: Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. The exact mechanism by which teriflunomide exerts its therapeutic effect in multiple sclerosis is unknown but may involve a reduction in the number of activated lymphocytes in CNS.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AUBAGIO · TERIFLUNOMIDE 7MG · TABLET, ORAL · Prescription · TE AB
  • AUBAGIO · TERIFLUNOMIDE 14MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Teriflunomide" as an intervention, any sponsor and status, largest first.

All 58 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • alopecia6,087
  • multiple sclerosis relapse5,245
  • fatigue4,771
  • diarrhoea4,764
  • fall3,354
  • hypoaesthesia3,173
  • headache3,007
  • drug ineffective2,833
  • paraesthesia2,816
  • nausea2,749
  • gait disturbance2,496
  • pain2,239

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20103
20112
201218
20131,900
20143,391
20152,733
20163,416
20174,323
20184,545
20194,640
20203,161
20216,639
20225,679
20232,621
2024938
2025660
2026437

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aubagio (Teriflunomide)

2024 spending

$148M

Beneficiaries

2,229

14,264 claims

Per beneficiary

$66,613

$302.42 per unit

View as table
YearSpending
2020$778,201,329
2021$724,520,395
2022$696,532,583
2023$353,934,133
2024$148,480,748

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 113 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.